Arqule Inc: (NASD: ARQL)
$2.43
0.06 (2.53%)
Volume 214,275
Jun 18 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 2.35 - 2.43 |
| 52wk Low - High | 1.98 - 6.98 |
| Previous Close | 2.37 |
| Avg. Volume | 308,777 |
| Industry | MED-DRUGS |
| Market Cap | 148.42 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.25 |
| P/E (F1) | 0.00 |
| Current Year Est. | -0.43 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
110 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.43 |
| Current Quarter Estimate | -0.11 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.20 |
| Expected Earnings Growth | NA |
Company Description
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.11 | -0.11 | -0.43 | -0.45 |
| Number of Estimates | 4 | 4 | 4 | 4 |
| Low Estimate | -0.13 | -0.13 | -0.50 | -0.59 |
| High Estimate | -0.09 | -0.09 | -0.36 | NA |
| Year Ago EPS | -0.01 | -0.01 | -0.18 | -0.43 |
| EPS Growth | -1,000.00% | -975.00% | -138.89% | -4.65% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ARQULE INC | ARQL | 2.37 | |
|
| JAZZ PHARMACEUT | JAZZ | 69.50 | |
|
| SALIX PHARM-LTD | SLXP | 66.21 | |
|
| SANTARUS INC | SNTS | 21.52 | |
|
| USANA HLTH SCI | USNA | 73.28 | |
|
| ARADIGM CORP | ARDM | 0.18 | |
|
| CELL THERAPEUT | CTIC | 1.25 | |
|
| DURECT CORP | DRRX | 0.81 | |
|
| ELAN CP PLC ADR | ELN | 13.49 | |
|
| FLAMEL TECH | FLML | 6.21 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Narrower-than-Expected Loss at ArQule
May 09, 2013
Data on ArQule's ARQ 092
Apr 10, 2013
ArQule Regains ARQ 092 Rights
Apr 02, 2013
ArQule's Loss Narrower than Expected
Mar 19, 2013
Pipeline Progess at ArQule
Feb 06, 2013
Synergy Starts SP-333 Phase I Study
Jan 29, 2013
Setback for ArQule, Shares Fall
Jan 14, 2013
Zacks #1 Rank Additions for Wednesday
Oct 03, 2012
Financials
| EPS TTM | -0.20 |
| Sales | 36 |
| Net Income | -12 |
| Price/Earnings | NA |
| Price/Book | 1.94 |
| Price/Cash Flow | NA |
| Price/Sales | 4.42 |
News
ArQule announces final data from Phase II colorectal cancer trial - Datamonitor
Jun 12, 2013
ArQule Announces Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer at ASCO - Benzinga
Jun 1, 2013
Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer Presented at ASCO 2013 - Businesswire
Jun 1, 2013
ArQule, Inc. to Present at Jefferies 2013 Global Healthcare Conference - Businesswire
May 30, 2013
ArQule Q1 net loss increases - Datamonitor
May 21, 2013
ArQule Posts 1Q 2013 Financial Results - Close-Up Media
May 12, 2013
ArQule IncCorporate Event Announcement Notice - Wall Street Horizon
May 9, 2013
ArQule IncCorporate Event Announcement Notice - Wall Street Horizon
May 8, 2013
Broker Recommendations
| Current ABR | 2.33 |
| ABR (Last Week) | 2.33 |
| # of recs in ABR | 6 |
| Average Target Price | 5.33 |
| Industry Rank by ABR | 110 out of 265 |
| Rank in Industry | 18 out of 95 |
